Servier paid Cellectis $10M upfront plus up to $140M per program in milestones across six allogeneic CAR-T candidates including lead UCART19 for B-cell leukemia. The pact was a precedent-setting bet on off-the-shelf gene-edited cell therapy and Servier later exercised its UCART19 option in November 2015.
Key facts
AnnouncedFeb 17, 2014
ClosedFeb 17, 2014
Deal value$850M
Deal typeCo-Development
Therapeutic areaB-cell leukemia (UCART19) and solid tumors
IndicationsB-cell leukemia (UCART19) and solid tumors
Key assetsUCART19 plus five solid-tumor allogeneic CAR-T candidates